Literature DB >> 34982555

Heterobivalent Ligand for the Adenosine A2A-Dopamine D2 Receptor Heteromer.

Daniel Pulido1,2, Verònica Casadó-Anguera3, Marc Gómez-Autet4, Natàlia Llopart3, Estefanía Moreno3, Nil Casajuana-Martin4, Sergi Ferré5, Leonardo Pardo4, Vicent Casadó3, Miriam Royo1,2.   

Abstract

A G protein-coupled receptor heteromer that fulfills the established criteria for its existence in vivo is the complex between adenosine A2A (A2AR) and dopamine D2 (D2R) receptors. Here, we have designed and synthesized heterobivalent ligands for the A2AR-D2R heteromer with various spacer lengths. The indispensable simultaneous binding of these ligands to the two different orthosteric sites of the heteromer has been evaluated by radioligand competition-binding assays in the absence and presence of specific peptides that disrupt the formation of the heteromer, label-free dynamic mass redistribution assays in living cells, and molecular dynamic simulations. This combination of techniques has permitted us to identify compound 26 [KDB1 (A2AR) = 2.1 nM, KDB1 (D2R) = 0.13 nM], with a spacer length of 43-atoms, as a true bivalent ligand that simultaneously binds to the two different orthosteric sites. Moreover, bioluminescence resonance energy transfer experiments indicate that 26 favors the stabilization of the A2AR-D2R heteromer.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34982555     DOI: 10.1021/acs.jmedchem.1c01763

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Chemical biology-based approaches to study adenosine A2A - dopamine D2 receptor heteromers.

Authors:  Karen J Gregory; Manuela Jörg
Journal:  Purinergic Signal       Date:  2022-03-29       Impact factor: 3.765

Review 2.  Adenosine receptor signalling in Alzheimer's disease.

Authors:  Phuc N H Trinh; Jo-Anne Baltos; Shane D Hellyer; Lauren T May; Karen J Gregory
Journal:  Purinergic Signal       Date:  2022-07-23       Impact factor: 3.950

3.  Editorial: purinergic signalling-perspectives from Australia and New Zealand.

Authors:  Ronald Sluyter; Jennie M E Cederholm; Srdjan M Vlajkovic
Journal:  Purinergic Signal       Date:  2022-10-11       Impact factor: 3.950

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.